NasdaqCM - Delayed Quote USD
bioAffinity Technologies, Inc. (BIAFW)
0.1711
+0.0011
+(0.65%)
At close: April 25 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Steven Girgenti | Founder & Executive Chairman of the Board | 115.43k | -- | 1946 |
| Ms. Maria Zannes J.D. | Founder, President, CEO & Director | 327.16k | -- | 1956 |
| Mr. Xavier T. Reveles M.S. | Chief Operating Officer | -- | -- | 1970 |
| Dr. William Bauta Ph.D. | Chief Science Officer | -- | -- | -- |
| Mr. Timothy P. Zannes J.D. | Executive VP, Secretary & General Counsel | -- | -- | 1953 |
| Ms. Julie Anne Overton | Director of Communications | -- | -- | -- |
| Mr. Dallas J. Coleman | Vice President of sales | -- | -- | -- |
bioAffinity Technologies, Inc.
3300 Nacogdoches Road
Suite 216
San Antonio, TX 78217
United States
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 57
Description
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Corporate Governance
bioAffinity Technologies, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available
Related Tickers
IZOZF Izotropic Corporation
0.1900
+5.56%
PRPH ProPhase Labs, Inc.
0.3030
-0.33%
NDRA ENDRA Life Sciences Inc.
3.2600
-46.99%
VCYT Veracyte, Inc.
29.71
-4.81%
MYGN Myriad Genetics, Inc.
3.8900
-3.47%
EXAS Exact Sciences Corporation
51.63
-2.70%
DHR Danaher Corporation
189.73
-2.61%
ILMN Illumina, Inc.
75.76
-4.80%
TMO Thermo Fisher Scientific Inc.
403.13
-1.86%